Verve Therapeutics Inc

NASDAQ:VERV  
52.25
+0.12 (+0.23%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Verve Therapeutics Inc Stock, NASDAQ:VERV

500 Technology Square, Suite 901, Cambridge, Massachusetts 02139
United States of America
Phone: +1.617.603.0070
Number of Employees:

Description

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan, and Burt A. Adelman in 2018 and is headquartered in Cambridge, MA.